Advancements and Updates in Therapies for CLL - Episode 1

NCCN Recommendations: Frontline CLL Treatment Options

Now Viewing
EP. 1: NCCN Recommendations: Frontline CLL Treatment Options
EP. 2: Front-Line Therapy Decision Criteria
EP. 3: Limited-Duration Therapy Based on MRD Testing
EP. 4: Newly Diagnosed CLL: BTK Inhibitor Monotherapy
EP. 5: Developing Clinical Trials for Newly Diagnosed Disease
EP. 6: First-Line Therapy for Treatment-Naïve Patients
EP. 7: BTK Inhibitor Toxicity Management
EP. 8: Oral Oncolytics Versus Intravenous: Safety and Efficacy
EP. 9: Oral Therapy Adverse Events
EP. 10: Intravenous Versus Oral Delivery: Medical Benefits
EP. 11: Pharmacy-Led Oral Chemotherapy Management Programs
EP. 12: Optimizing Success for Community Physicians
EP. 13: Experts Outline Best Practices in the Treatment of Chronic Lymphocytic Leukemia
EP. 14: Experts Discuss Treatment Considerations for Chronic Lymphocytic Leukemia

In this Directions in Oncology Pharmacy Insights video series, Alison Duffy, PharmD, BCOP, University of Maryland School of Pharmacy, and Cody Steeves, PharmD, BCOP, Biologics by McKesson, discuss advancements and updates in therapies for chronic lymphocytic leukemia (CLL). This first segment focuses on NCCN recommendations for frontline treatment options.